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license (http://creativerent evidence is based on three studies in patients with Alzheimer’s disease and one study in patients
with mild cognitive impairment which all together included only 1756 patients. Importantly, two of
these studies were negative, and the two other studies had severemethodological weaknesses that pre-
clude more definite interpretation. Based on the notion from patients suffering from cerebrovascular
diseases that vitamin E may induce serious side effects (i.e., hemorhagic stroke), vitamin E cannot be
recommended for use in Alzheimer’s patients.
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4.0/).Keywords: Alpha-tocopherol; Cognition; Dementia; Free radical scavengerThe lipophilic antioxidant vitamin E (a-tocopherol) vividly
interacts with cell membranes, scavenging free radicals and
thereby interrupting chain reactions resulting in neuronal
injury [1]. Because of its property as free radical scavenger,
neuroprotective effects of vitamin E have been postulated in
cerebrovascular and neurodegenerative diseases over many
years, which have been proven in experimental disease
models [2]. In cerebrovascular diseases, a meta-analysis
based on 9 randomized, placebo-controlled studies with
1-year follow-up and a total number of 118,765 subjects
(59,357 on vitamin E and 59,408 on placebo) demonstrated
that vitamin E delivery at variable doses (50–800 mg/day)
had beneficial effects on ischemic stroke incidence (relative
risk 0.90 [95% confidence interval 0.82–0.99]) [3].
Regarding Alzheimer’s disease, considerably less evidence
supports the therapeutic efficacy of vitamin E, as pointed
out in a recent article [4] and again summarized in the pre-
sent issue of Alzheimer’s Dementia: Translational Research
and Clinical Interventions [5]. Indeed, the present data evi-
dence is basically based on four studies:
(1) The double-blind, placebo-controlled, randomized
multicenter study of the American Alzheimer’s Dis-uthor. Tel.: 149-201-723-2814; Fax: 149-201-723-
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commons.org/licenses/by-nc-nd/4.0/).ease Cooperative Study (ADCS) group evaluated ef-
fects of vitamin E (2000 IU/day) in 341 patients with
moderate Alzheimer’s disease (Clinical Dementia
Rating [CDR] Scale 2) over an observation period
of 2 years either alone or in combination with the
monoamine oxidase B inhibitor selegiline [6].
Compared with placebo, vitamin E significantly de-
layed the primary endpoint, which was the develop-
ment of severe dementia [CDR Scale 3], nursing
home referral, or death (P5 .001). A major criticism
relates to the fact that baseline Mini-Mental State Ex-
amination (MMSE) score varied statistically tenden-
tially but considerably regarding its parameter value
between the placebo group (13.36 4.9) and the three
other groups (11.36 5.7 [vitamin E], 12.76 5.0 [se-
legiline], and 12.96 5.7 [vitamin E plus selegiline]).
Baseline MMSE was highly predictive for the pri-
mary endpoint in this cohort (P 5 .012). Similar to
vitamin E, selegiline also postponed the primary
endpoint in this study. Considering the small cohort
recruited, the size of groups was small (84–87 pa-
tients per group). Despite adjustment for baseline
MMSE, the relevance of these findings is question-
able. The primary endpoint did not differ between
groups in nonadjusted analyses.
(2) The more recent Trial of Vitamin E and Memantine
in Alzheimer’s Disease was a double-blind,r’s Association. This is an open access article under the CC BY-NC-ND
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613 patients with mild or moderate Alzheimer’s dis-
ease (MMSE score 12–26) on choline esterase inhib-
itors receiving vitamin E (2000 IU/day), memantine
(20 mg/day), or vitamin E plus memantine (2000
IU/day/20 mg/day) [7]. Over a mean observation
period of 2.77 years, the delivery of vitamin E slowed
down the decline of the ADCS activities of daily
living (ADCS-ADL) score (mean difference
compared with placebo: 3.15 [confidence interval
0.92–5.39]). In patients receiving memantine,
vitamin E notably did not affect the decline of the
ADCS-ADL score (mean difference to placebo:
1.98 [20.24 to 4.20] for memantine and 1.76
[20.48 to 4.00] for vitamin E plus memantine),
which has to be interpreted as evidence for noneffi-
cacy of vitamin E treatment. Convincing rationales
for the lack of therapeutic response of vitamin E un-
der simultaneous memantine treatment is lacking,
particularly as patients receiving vitamin E plus
memantine performed worse than patients receiving
memantine only. Larger patient samples will be
required to evaluate effects of vitamin E more consis-
tently in both groups.
(3) A double-blind, placebo-controlled, randomized,
explorative monocenter study from Spain examined
effects of vitamin E (800 IU/day) in 57 patients
with mild, moderate, or severe Alzheimer’s disease,
of which only 33 patients could be included into
the statistical analysis, because they continued the
study over the entire observation period of 6 months
[8]. In the total cohort, vitamin E did not influence the
change of cognitive performance, which was evalu-
ated by the MMSE score, the Blessed Dementia
Scale, and the clock test. In a subsequent analysis
of the blood oxidized glutathione (GS-SG) value,
only 9 of 19 patients exhibited a decrease of blood
GS-SG during vitamin E treatment (so-called re-
sponders). In the latter patients, cognitive perfor-
mance did not change in response to vitamin E
treatment. In the 10 patients not exhibiting a decrease
of blood GS-SG (so-called nonresponders), the
MMSE score worsened significantly during vitamin
E treatment. The conclusions of this study are
confined by its pilot character without predefined
endpoints and the low protocol adherence of partici-
pants. The study was interpreted as a possible evi-
dence for a detrimental effect of vitamin E.
(4) The double-blind, placebo-controlled, randomized
multicenter study of the ADCS group on 769 patients
with mild cognitive impairment (CDR Scale 0.5)
evaluated effects of vitamin E (2000 IU/day) or done-
pezil (10 mg/day) over an observation period of
3 years [9]. Vitamin E treatment did not affect the pri-
mary endpoint, which was the development ofpossible or probable Alzheimer’s disease (hazard ra-
tio 1.02 [confidence interval 0.74–1.41]). Donepezil
also did not influence disease progression over 3 years
(0.80, 0.57–1.13).
In summary, the two favorable studies on patients with Alz-
heimer’s disease had severe methodological weaknesses. In
the first study, the baseline MMSE score varied considerably
between groups [6]. In the second study, vitamin E improved
disease development when administered alone but not when
administered in patients receiving memantine [7]. The third
study on patients with Alzheimer’s disease [8] and the only
study on patients suffering from mild cognitive impairment
[9] were negative. The total number of patients recruited in
the four studies was small (1756 patients).
In stroke, vitamin E therapy is not recommended in clinical
practice despite much larger studies with less methodolog-
ical weaknesses. Although vitamin E reduced ischemic
stroke incidence in the previous meta-analysis [3], it
increased hemorrhagic stroke risk (relative risk 1.22 [1.00–
1.48]). Total stroke risk was unaffected in this meta-
analysis (0.98 [0.91–1.05]). Based on the current state of
knowledge, there is little evidence that vitamin E improves
the course of Alzheimer’s disease. On the contrary, serious
concerns have to be raised that adverse effects of vitamin
E unraveled in the stroke studies (i.e., increase of hemor-
rhagic stroke risk) may impose risks to Alzheimer’s patients.
Another meta-analysis showed that vitamin E increased
mortality in patients suffering from cerebrovascular or car-
diovascular diseases but in tendency reduced mortality in pa-
tients without cerebrovascular or cardiovascular diseases
[10]. Whether Alzheimer patients, which as a matter of
fact often have vascular comorbidities (namely cerebral mi-
croangiopathy), rather belong to the first or secondary cate-
gory should be evaluated in larger controlled trials. Based on
current evidence, vitamin E treatment cannot be recommen-
ded in Alzheimer’s disease.
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